Anavex Life Sciences Corp. (NASDAQ: AVXL)

Sector: Healthcare Industry: Biotechnology CIK: 0001314052
P/B 3.64
P/E -7.44
P/S 0.00
Market Cap 345.25 Mn
ROIC (Qtr) -55.33
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00

About

Anavex Life Sciences Corp., often recognized by its stock symbol AVXL, operates in the biopharmaceutical industry with a focus on developing differentiated therapeutics for central nervous system (CNS) diseases through precision medicine. The company's primary product candidate is ANAVEX2-73 (blarcamesine), which is being developed to treat Alzheimer's disease, Parkinson's disease, and other CNS disorders, including rare diseases like Rett syndrome. Anavex Life Sciences Corp.'s main business activities involve the creation of innovative therapeutics...

Read more

Stock Price Chart

Analysis

Pros

  • Tangible assets of 103.81M provide exceptional 128.96x coverage of deferred revenue 805000, showing strong service capability backing.
  • Operating cash flow of (39.04M) fully covers other non-current liabilities (805000) by 48.50x, showing strong long-term stability.
  • Tangible assets of 103.81M provide robust 22.10x coverage of other current liabilities 4.70M, indicating strong asset backing.
  • R&D investment of 37.59M represents healthy 46.70x of deferred revenue 805000, indicating strong future innovation pipeline.
  • Cash reserves of 102.58M provide robust 11.47x coverage of current liabilities 8.95M, indicating strong short-term solvency.

Cons

  • Investment activities of 0 provide weak support for R&D spending of 37.59M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of (39.04M) provides insufficient coverage of deferred revenue obligations of 805000, which is -48.50x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of (39.04M) shows concerning coverage of stock compensation expenses of 11.55M, with a -3.38 ratio indicating potential earnings quality issues.
  • Operating cash flow of (39.04M) is outpaced by equity issuance of 12.14M (-3.22 ratio), indicating concerning reliance on equity markets for funding operations.
  • Tangible assets of 103.81M provide limited backing for working capital of 94.87M, which is 1.09x, suggesting increased operational risk in market downturns.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 2.35 12.31
EV to Cash from Ops. -6.25 23.25
EV to Debt 0.00 738.44
EV to EBIT -5.26 -9.16
EV to EBITDA -4.75 6.95
EV to Free Cash Flow [EV/FCF] -6.25 21.90
EV to Market Cap 0.71 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 3.64 22.34
Price to Earnings [P/E] -7.44 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 0.00 -27.13
Cash and Equivalents Growth (1y) % -22.40 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -7.85 -46.93
EBITDA Growth (1y) % 2.78 -1.68
EBIT Growth (1y) % -7.85 -56.45
EBT Growth (1y) % -7.85 -12.70
EPS Growth (1y) % -3.85 -28.31
FCF Growth (1y) % -26.72 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 11.47 3.85
Current Ratio 11.61 7.27
Debt to Equity Ratio 0.00 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22